Pulmonary Medicine Clinical Trials
Clinical trials in Pulmonary Medicine provide an important step in discovering new treatments. You can browse the list of current clinical trials below to learn more.
Trials
D3250R00107 – BURAN: Effects of Benralizumab in Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging Parameters
The aim of this study is to learn more about the drug called benralizumab (Fasenra®) and to better understand how it works in the treatment of severe eosinophilic asthma.
Sponsor: AstraZeneca
NCT05552508
Identification of Immunological Host Defense Mechanisms Against Nontuberculous Mycobacteria: A pilot Study to Measure Immune Response in Patients with and without Nontuberculous Mycobacterial (NTM) Infection
The purpose of this study is to gain insight into the factors that contribute to protection against NTM. It is hoped that information collected from this study will lead to new treatment options to improve outcomes of patients infected with NTM.
Sponsor: Grant
IRB #: 1085
Multicenter randomized pragmatic clinical trial comparing two-versus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease
The purpose of this study is to compare the effectiveness and tolerability of a 2-study drug treatment regimen and a 3-study drug treatment regimen in subjects who have recently been diagnosed with pulmonary (lung) disease caused by Mycobacterium avium complex (MAC).
Sponsor: PCORI
IRB#: 1084
Bronchiectasis Registry
The purpose of the program is to identify a group of people who are interested in receiving information about research studies focused on bronchiectasis and/or non-tuberculosis mycobacteria (NTM) and possibly participating in these research studies.
Sponsor: COPD Foundation
IRB#: 872
CF Registry
The goal of the Patient Registry is to collect data on individuals with cystic fibrosis (CF) to better understand the illness and ultimately improve the care and survival of those with CF.
Sponsor: CFF
IRB#: 678
Study to Evaluate the Safety, Efficacy, and Pharmacology of ARINA-1
RVN-301 – A Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and pharmacology of ARINA-1 administered twice daily by nebulizer in adult participants with non-cystic fibrosis bronchiectasis (NCFBE) with excess mucus and cough.
Sponsor: Renovion, Inc.
NCT05495243
Study to Assess to Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole
MACrO2 – A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Prospective Study to Assess to Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with treatment-Refractory Mycobacterium avium Complex Lung Disease – Protocol EBO-301
Sponsor: AN2 Therapeutics
IRB#: 2022-029
Study Evaluating Efficacy, Safety, and Tolerability of BI 1291583 qd
1397-0012 – A randomized, double-blind, placebo-controlled, parallel-group, dose-finding study evaluating efficacy, safety, and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis
Sponsor: BI
NCT05238675
Development of a nontuculous mycobaterial pulmonary disease symptom scale
Development of a nontuberculous mycobaterial pulmonary disease symptom scale
Sponsor: FDA
IRB#: 2022-011
Study to Evaluate the Efficacy, Safety Tolerability and Pharmacokinetics of Oral Omadacycline in Treatment-Naïve Adults Subjects with Nontuberculous Mycobaacterial (NTM) Pulmonary Disease
PTK0796-NTM-20203 – A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety Tolerability and Pharmacokinetics of Oral Omadacycline in Treatment-Naïve Adults Subjects with Nontuberculous Mycobaacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus complex (MABc)
Sponsor: Paratek
NCT04922554
Study of the Safety and Pharmacokinetics of AR-501 (gallium citrate)
AR-501-001 – A Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of the safety and pharmacokinetics of AR-501 (gallium citrate), administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis subjects
Sponsor: Aridis
NCT03669614
Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection
ENCORE 416 – A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
Sponsor: Insmed
NCT04677569
Study of RHB-204 for the Treatment of Pulmonary Mycobacterium avium Complex (MAC) Disease
Study of RHB-204 for the Treatment of Pulmonary Mycobacterium avium Complex (MAC) Disease in Adults with Nodular Bronchiectasis (CleaR-MAC Trial)
Sponsor: Redhill Biopharma
NCT04616924
Qualitative Development and Psychometric Validation of a Clinical Outcome Assessment (COA) Tool
Qualitative Development and Psychometric Validation of a Clinical Outcome Assessment (COA) Tool for Bronchiectasis
Sponsor: Insmed
IRB#: 1120
BRONCH Study
BRONCH Study (Bronchiectasis Results Of Natural Clinical History)
Sponsor: UTHSCT
IRB#: 1116
Clinical Effectiveness Of High Frequency Chest Wall Oscillation (HFCWO)
Clinical Effectiveness Of High Frequency Chest Wall Oscillation (HFCWO) In A Bronchiectasis Population
Sponsor: Electromed
NCT04271969
Alvelestat (MPH996) for the Treatment of Alpha-1 Antitrypsin Deficiency (ATLANTa)
Alvelestat (MPH996) for the Treatment of Alpha-1 Antitrypsin Deficiency (ATLANTa) – A Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of Alvelestat (MPH996) in alpha-1 antitrypsin deficiency
Sponsor: Mereo
IRB#: 1090
Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections
Multiple Patient Program for Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections
Sponsor: Novartis
NCT04334070
Clofazimine in the treatment of pulmonary Mycobacterium avium complex (MAC) disease
Clofazimine in the treatment of pulmonary Mycobacterium avium complex (MAC) disease
Sponsor: OHSU
NCT02968212
Weekly Intravenous Alpha1-Proteinase Inhibitor (Human) in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human) in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency
Sponsor: Grifols
NCT01983241
